Autoimmune encephalitis and immune therapy: lessons from Argentina

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Autoimmune encephalitis (AE) is a frequent cause of noninfectious acute encephalitis.
• Understanding immune therapy regimens in Latin America is crucial for AE management.

Purpose of the Study:

• To review immune therapy regimens, safety, and efficacy in Argentine AE patients (2013-2018).
• To assess the impact of early and aggressive immunosuppressive therapy on AE outcomes.

Main Methods:

• Retrospective review of medical records from ten AE patients.
• Data collection included clinical, laboratory, imaging, and CSF findings, plus neoplasm screenings.
• Analysis of first- and second-line immunotherapy regimens, including rituximab, methylprednisolone, and azathioprine.

Main Results:

• Ten AE patients received first-line immunotherapy at a median of 2.5 months post-onset.
• Five patients required second-line treatment; outcomes improved significantly (median modified Rankin Scale decreased from 5 to 1).
• Two relapses occurred, both in patients treated with methylprednisolone and IVIG; subsequent treatment with rituximab, corticoids, and azathioprine prevented further relapses.

Conclusions:

• Early and aggressive immunosuppressive therapy is vital for favorable clinical outcomes in AE.
• Timely intervention promotes fast recovery and reduces the risk of disease relapse.
• Specific regimens like rituximab, methylprednisolone, and azathioprine show efficacy in managing AE.